Logo image of ACER

ACER THERAPEUTICS INC (ACER) Stock Fundamental Analysis

NASDAQ:ACER - Nasdaq - US00444P1084 - Common Stock - Currency: USD

0.9  +0.03 (+3.41%)

After market: 0.8005 -0.1 (-11.06%)

Fundamental Rating

0

Taking everything into account, ACER scores 0 out of 10 in our fundamental rating. ACER was compared to 193 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of ACER have multiple concerns. ACER has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ACER had negative earnings in the past year.
In the past year ACER has reported a negative cash flow from operations.
In the past 5 years ACER always reported negative net income.
In the past 5 years ACER always reported negative operating cash flow.
ACER Yearly Net Income VS EBIT VS OCF VS FCFACER Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -225.71%, ACER is not doing good in the industry: 92.72% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -225.71%
ROE N/A
ROIC N/A
ROA(3y)-141.6%
ROA(5y)-120.76%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ACER Yearly ROA, ROE, ROICACER Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 200 -200 400 -400 600 800

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ACER so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACER Yearly Profit, Operating, Gross MarginsACER Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 -200 -400 -600 -800 -1K

More info and screens

0

2. Health

2.1 Basic Checks

ACER does not have a ROIC to compare to the WACC, probably because it is not profitable.
ACER has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, ACER has a worse debt to assets ratio.
ACER Yearly Shares OutstandingACER Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M
ACER Yearly Total Debt VS Total AssetsACER Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

2.2 Solvency

ACER has an Altman-Z score of -25.07. This is a bad value and indicates that ACER is not financially healthy and even has some risk of bankruptcy.
ACER has a worse Altman-Z score (-25.07) than 91.75% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -25.07
ROIC/WACCN/A
WACC9.13%
ACER Yearly LT Debt VS Equity VS FCFACER Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M

2.3 Liquidity

ACER has a Current Ratio of 0.19. This is a bad value and indicates that ACER is not financially healthy enough and could expect problems in meeting its short term obligations.
ACER's Current ratio of 0.19 is on the low side compared to the rest of the industry. ACER is outperformed by 97.09% of its industry peers.
ACER has a Quick Ratio of 0.19. This is a bad value and indicates that ACER is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of ACER (0.19) is worse than 96.12% of its industry peers.
Industry RankSector Rank
Current Ratio 0.19
Quick Ratio 0.19
ACER Yearly Current Assets VS Current LiabilitesACER Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for ACER have decreased strongly by -88.64% in the last year.
ACER shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)-88.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-74.19%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, ACER will show a very strong growth in Earnings Per Share. The EPS will grow by 35.01% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y55.45%
EPS Next 2Y44%
EPS Next 3Y35.01%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACER Yearly Revenue VS EstimatesACER Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2021 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M
ACER Yearly EPS VS EstimatesACER Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10 -20 -30 -40

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ACER. In the last year negative earnings were reported.
Also next year ACER is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACER Price Earnings VS Forward Price EarningsACER Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACER Per share dataACER EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5

4.3 Compensation for Growth

ACER's earnings are expected to grow with 35.01% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44%
EPS Next 3Y35.01%

More info and screens

0

5. Dividend

5.1 Amount

ACER does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACER THERAPEUTICS INC

NASDAQ:ACER (11/8/2023, 8:19:05 PM)

After market: 0.8005 -0.1 (-11.06%)

0.9

+0.03 (+3.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-15 2023-11-15/amc
Earnings (Next)03-25 2024-03-25/amc
Inst Owners1.19%
Inst Owner Change0%
Ins Owners0.02%
Ins Owner Change0%
Market Cap22.01M
Analysts80
Price Target1.53 (70%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.22%
Min EPS beat(2)-43.08%
Max EPS beat(2)55.52%
EPS beat(4)2
Avg EPS beat(4)8%
Min EPS beat(4)-51.19%
Max EPS beat(4)70.76%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-86.36%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-6.62%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-16.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.66
EYN/A
EPS(NY)-0.74
Fwd EYN/A
FCF(TTM)-1.24
FCFYN/A
OCF(TTM)-1.24
OCFYN/A
SpS0
BVpS-0.69
TBVpS-1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -225.71%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-141.6%
ROA(5y)-120.76%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score0
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 259.19%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.19
Quick Ratio 0.19
Altman-Z -25.07
F-Score0
WACC9.13%
ROIC/WACCN/A
Cap/Depr(3y)116.99%
Cap/Depr(5y)196.86%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-88.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-74.19%
EPS Next Y55.45%
EPS Next 2Y44%
EPS Next 3Y35.01%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-91.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-15924.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-22323.8%
OCF growth 3YN/A
OCF growth 5YN/A